Effects of sorafenib on primary DLBCL and MCL cells.
收藏数据链接：
官方服务：
资源简介：
Freshly isolated blood MNCs from DLBCL and MCL patients were resuspended (1×106/ml) in RPMI-1640 supplemented with FBS (10%, v/v) and incubated (24 hours, 37°C, 5% CO2) with sorafenib (5–10 µM). Controls were supplemented with DMSO. At the end of the incubation, viable cell counts (Annexin-V-/PI-) were evaluated by Flow-Count beads and Annexin-V/PI double staining. Data are expressed as percent of control.
创建时间：
2015-12-02
